Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > How Low Can It Go?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(99)
•••
Comment by Aarcoron May 06, 2021 11:20am
120 Views
Post# 33140690

RE:RE:RE:RE:RE:RE:How Low Can It Go?

RE:RE:RE:RE:RE:RE:How Low Can It Go?Well perhaps you're just more interested in needing to be right about xb3 rather than having any concern for the investment.

If I were to review your historical posts (which I won't) I would not find a single post where you have indicated you have actually bought any shares in the last 5+ years.  It's not clear if you're a shareholder, paid shill or just someone fascinated by the potential science breakthrough.  Unfortunately, if the latter, management has not been able to get it past mice for a decade.

Frustrated shareholders get tired of a 10-year history of wrong dogmatic writings and constant support of incompetent management creating and supporting a business plan that has ceded control to, and is entirely dependent on, the priorities and interests of pharma.  The share price is a reflection of that.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities